

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 November 2023 (23.11.2023)



(10) International Publication Number
WO 2023/225162 A1

(51) International Patent Classification:

C07D 209/12 (2006.01) C07D 417/02 (2006.01)
C07D 401/10 (2006.01) A61P 31/12 (2006.01)
C07D 403/10 (2006.01) A61K 31/404 (2006.01)
C07D 405/14 (2006.01)

(21) International Application Number:

PCT/US2023/022679

(22) International Filing Date:

18 May 2023 (18.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/344,487 20 May 2022 (20.05.2022) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **CHO, Aesop**; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). **DE LA
FUENTE, Katherine**; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US). **STRAT-
TON, Thomas P.**; c/o Gilead Sciences, Inc., 333 Lake-
side Drive, Foster City, California 94404 (US). **WANG,
Peiyuan**; 1648 Toyon Court, San Mateo, California 94403
(US). **WATKINS, William J.**; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
XU, Jie; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Fos-
ter City, California 94404 (US). **YANG, Kin S.**; 876 Ursa
Lane, Foster City, California 94404 (US).

(74) Agent: **LIU, Jiangqiong** et al.; Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOF

(57) Abstract: The present disclosure relates to indolinyl compounds. The present disclosure further relates to compounds that inhibit viral helicase-primase. The present disclosure further relates to the use of the compounds for the preparation a medicament for the treatment of diseases and/or condition through inhibiting viral helicase-primase. The present disclosure also relates to use of those compounds in the treatment of viral infections. The present disclosure further relates to intermediates for its preparation and to pharmaceutical compositions containing those compounds.



WO 2023/225162 A1